Oncology Products – Page 2

Occupational exposure limit breach during stability pull: risk assessment for patient safety

Recognizing the symptoms of an OEL breach during stability pulls is critical for timely intervention. Key indicators may include:Click to read the full article.

Assay drift during stability pull: FDA/EMA investigation expectations

Detection of assay drift during stability pulls often starts with subtle signals that can escalate into a significant quality concern. Recognizing these symptoms early is paramount for effective investigation and…

Cross-contamination risk during shared facility campaign: containment CAPA and effectiveness checks

Recognizing the symptoms of cross-contamination is crucial for timely response. Symptoms may manifest in several ways:Click to read the full article.

Assay drift during shared facility campaign: containment CAPA and effectiveness checks

The first step in addressing assay drift is identifying observable symptoms or signals during manufacturing processes or laboratory testing. Symptoms may appear as:Click to read the full article.

Potency OOS during stability pull: risk assessment for patient safety

Identifying the symptoms associated with a potency OOS result is crucial to initiating an effective investigation. Symptoms typically observed might include:Click to read the full article.

Assay drift in oncology manufacturing: FDA/EMA investigation expectations

Detection of assay drift typically arises during routine operations through various signals that indicate a potential quality issue. Common symptoms include:Click to read the full article.

Cross-contamination risk after equipment cleaning: FDA/EMA investigation expectations

Identifying the early signals of cross-contamination is crucial for timely intervention. Common symptoms might include:Click to read the full article.

Potency OOS after equipment cleaning: FDA/EMA investigation expectations

When dealing with a potency OOS following equipment cleaning, clear signals can help identify the immediate need for an investigation. Common symptoms include:Click to read the full article.

Stability failure during shared facility campaign: risk assessment for patient safety

Identifying symptoms and signals early in the manufacturing process is critical to mitigating stability failures. Common indicators on the production floor or in the laboratory may include:Click to read the…

Potency OOS after equipment cleaning: containment CAPA and effectiveness checks

The identification of signals suggesting potential potency OOS following equipment cleaning is crucial. Symptoms might manifest during routine quality control testing or inadvertently during a production run. Common indicators can…

Stability failure during inspection prep: risk assessment for patient safety

Detecting signals of stability failure requires vigilance across manufacturing, quality control, and storage environments. Common symptoms may include:Click to read the full article.

Occupational exposure limit breach during stability pull: containment CAPA and effectiveness checks

The initial identification of an OEL breach is typically characterized by several observable cues in both manufacturing and laboratory environments. Symptoms often manifest as chemical exposure indicators, abnormal employee health…